We investigated the variability in infectivity of cells in primary brain tumor samples from different patients using an HSV-1 amplicon vector. We studied the infectivity of HSV-1 amplicon vectors in tumor samples derived from neurosurgical resections of 20 patients. Cells were infected with a definite amount of HSV-1 amplicon vector HSV-GFP. Transduction efficiency in primary tumor cell cultures was compared to an established human glioma line. Moreover, duration of transgene expression was monitored in different tumor cell types. All primary cell cultures were infectable with HSV-GFP with variable transduction efficiencies ranging between 3.0 and 42.4% from reference human Gli36DEGFR glioma cells. Transduction efficiency was significantly greater in anaplastic gliomas and meningiomas (26.7717.4%) compared to more malignant tumor types (glioblastomas, metastases; 11.278.5%; P ¼ 0.05). To further investigate the possible underlying mechanism of this variability, nectin-1/HevC expression was analyzed and was found to contribute, at least in part, to this variability in infectability. The tumor cells expressed the exogenous gene for 7 to 61 days with significant shorter expression in glioblastomas (18713 d) compared to anaplastic gliomas (42724 d; Po0.05). Interindividual variability of infectivity by HSV-1 virions might explain, at least in part, why some patients enrolled in gene therapy for glioblastoma in the past exhibited a sustained response to HSV-1-based gene-and virus therapy. Infectivity of primary tumor samples from respective patients should be tested to enable the development of efficient and safe herpes vector-based gene and virus therapy for clinical application. Gene Therapy (2005) 12, 588-596.
Introduction
Gliomas are the most common primary intracranial neoplasms. Grading is performed according to the World Health Organization (WHO), taking into account histopathological criteria. 1, 2 Glioblastoma, corresponding to WHO Grade IV, is the most fatal and most common primary brain neoplasm, and about 50% of all gliomas are glioblastomas. 3 In view of the high incidence (10-15/ 100 000) and poor prognosis of malignant brain tumors treated with conventional therapies, such as surgery, chemotherapy, brachy-and radiotherapy, 4 research focusing on the elucidation of tumor biology and cell cycle regulation as well as on the development of clinically effective gene therapies is of utmost importance. Localized transduction of brain tumor cells with therapeutic genes may influence their biological properties by rendering them sensitive to prodrugs, by altering the expression of cell-cycle regulating proteins, by inhibiting angiogenesis, by stimulating the immune response or by triggering apoptosis. An additional approach consists of the selective oncolysis of tumor cells mediated by certain mutant herpes or adenoviruses. [5] [6] [7] [8] [9] [10] [11] [12] The helper virus-free HSV-1 amplicon has been shown to be a safe and efficient vector system in culture and in vivo to transduce various central nervous system-derived cells including human gliomas. 8, [13] [14] [15] [16] Further development of gene therapy protocols for use in patients is an important, but, according to experience, also quite a challenging issue. This could be due to, at least in part, different responsiveness of different tumor types to (i) the gene paradigm used (eg prodrug therapy), and also (ii) to the interindividual variability of cells within the same tumor to vector infectivity. Maleniak et al 17 exposed five human glioblastoma cell cultures from surgical biopsies to different gene therapy approaches and found noticeable differences in their responsiveness toward therapy. These intercellular differences in malignant brain tumors have not been adequately addressed in current clinical gene therapy protocols. Therefore, we have tested the infectability of different primary brain tumor samples with helper virusfree HSV-1 amplicon vectors to evaluate the interindividual differences in the efficiency of this transduction.
Results
In total, neurosurgical samples from 42 patients were collected and processed for primary cell culture. In all, 20/42 samples grew and were expanded as proliferating primary tumor cell culture. In total, 12 glioblastomas (WHO grade IV), three anaplastic (WHO grade III) gliomas (one astrocytoma, one oligoastrocytoma, one oligodendroglioma), four metastases (two lung cancers, one breast cancer and one melanoma metastasis) and one meningioma (WHO grade I) were analyzed after one passage in culture (Table 1) . A total of 22 samples did not attach to cell culture plates and died (eight glioblastomas WHO grade IV, three anaplastic gliomas WHO grade III, two gliomas WHO grade II, six metastases, one meningioma and two nontumoral lesions).
Characterization of primary cell culture
The proliferative behavior of tumor cells grown as primary cell culture was variable. To determine roughly proliferative activity of primary tumor samples in culture, the time span to form nearly confluent monolayers (time until confluency, t.u.c.) was assessed. The t.u.c. was highly variable ranging between 5 and 56 days for all cultures (mean: 21716 d). Subdivided for the different tumor types, the t.u.c. was 25717 d for glioblastomas, 26720 d for anaplastic gliomas, 1074 d for metastases and 7 d for the meningioma (Table 1) . Comparing the t.u.c. of the gliomas (GB and anaplastic gliomas; 25717 d) with the t.u.c. of the metastases and the meningioma (974 d), a statistical significant difference could be observed (P ¼ 0.05). In most tumors, Ki67 staining of tumor material was performed to determine the proliferative activity of the original tumor in vivo (Table 1 ). However, due to different proliferative behavior of original tumor tissue and tumor tissue grown in primary cell culture, the results of Ki67 staining did not correspond to the t.u.c. of cells in culture.
Cells from each primary cell culture were incubated with anti-GFAP. All glioblastomas and the astrocytoma showed various degrees of GFAP immunoreactivity (Table 1, Figure 1 ). No sample exhibited 100% GFAP staining, indicating the presence of mixed tumor samples. The oligo astrocytoma, the oligodendroglioma, all four metastases and the meningioma were GFAP negative.
Transduction efficiency after HSV-GFP infection
To determine the transduction efficiency of HSV-1 amplicon vectors for each primary cell culture, the number of GFP-expressing cells after infection was counted as well as for Gli36DEGFR and baby hamster kidney (BHK) cells in parallel. In Gli36DEGFR cells, infection with HSV-GFP amplicon vector caused nearly all cells to express GFP, a mean number of 7.6 Â 10 Figure 1 shows representative images of GFP fluorescence after HSV-GFP infection of different tumor types.
Duration of gene expression
To assess the duration of exogenous gene expression, GFP expression was monitored over time. To assess whether the duration of gene expression was related to the primary transduction efficiency and proliferative activity of the tumor samples, regression analyses were performed. For each tumor type, a higher primary transduction efficiency was associated with a longer duration of GFP expression ( Figure 2 ). Moreover, for glioblastomas, a longer t.u.c. -indicating low proliferation activity -was associated with a longer duration of GFP expression.
Herpes entry receptor status
To further investigate the reason for different infectivity of the brain tumor samples, we tested the status of HSV-1 entry receptors in a subset of five primary cell cultures. Nectin-1/HveC was chosen as the most relevant herpes entry mediator for HSV-1 in the brain. Staining tumor cells against nectin-1 that had previously been transduced with HSV-GFP revealed that only tumor cells expressing nectin-1/HveC had actually been transduced (Figure 3 ), but not all nectin-1/HveC-positive cells were transduced with HSV-GFP.
Discussion
The purpose of this study was to test the variability of the infectivity of brain tumor samples from different patients with an HSV-1 amplicon vector. We found an up to 13.9-fold difference in the transduction efficiency of HSV-1 amplicon vectors between tumors of various types from different patients. The differences of infectivity could not be attributed entirely to tumor type. Our results indicate that all tumor types tested are susceptible to infection with the HSV-1 amplicon vector and could be approached by gene therapy using herpes-derived vectors. However, the therapeutic response would probably vary depending on the infectivity of individual tumors. Therefore, testing of individual tumor samples for infectivity by herpes virions could be a valuable tool not to select specifically patients for herpes-mediated gene-and virus therapy but to learn why therapy is efficient in one patient and not in the other.
Many properties of HSV-1 are especially suitable for using this virus as a vector to treat diseases affecting the central nervous system, namely its natural neurotropism, high transduction efficiency, large transgene capacity and the ability of entering a latent state in neurons. 8, 18 Two different HSV-1-based vector types, recombinant as well as 'gutless' HSV-1 amplicon vectors, can be distinguished. Recombinant HSV-1 vectors (replicationdefective or replication-conditional) have been designed for brain tumor treatment to kill selectively tumor cells by virus replication and/or to express antitumor acting therapeutic genes. Thereby, the efficiency of HSV-1-mediated virus-and gene therapy depends on (i) the infectivity of the viral vector and (ii) the replication ability of the replication-conditional vector within the tumor. Over the past 10 years, different single-and multiple-mutated replication-conditional HSV-1 vectors have been generated. Examples of HSV-1 viruses in which the g34.5 gene (encoding a so-called 'neurovirulence factor') has been deleted are HSV-1 mutants 1716 and G207. [19] [20] [21] [22] The HSV g34.5 gene counteracts the interferon-induced block -mediated by a dsRNAdependent protein kinase -to virus replication. This is usually disabled in tumor cells, allowing for viral replication there. Other HSV-1 mutants successfully applied in experimental glioma virus therapy have been summarized in Jacobs et al. 
and G207 have been successfully moved toward clinical application. They both were tested in patients with recurrent and/or newly diagnosed glioblastomas with some slowing of the progression of the disease in single patients with small tumors. 10, 12, 23 However, in these studies, it has been documented that the replicative ability in vivo correlates inversely to the immune status of the patient. In the study by Papanastassiou et al, 23 active 1716 replication could be documented in patients with low anti-HSV-1 antibody titers. Moreover, reduced efficacy of replication has been reported in the presence of high HSV-1 antibody titers in murine models. [24] [25] [26] It should be pointed out that by using replication-defective vectors (see below), pre-existing immunity does not influence transduction efficiency. 27, 28 Therefore, the patient's antibody titers should have no influence on the infectivity of HSV-1 amplicon vectors. Nevertheless, the infectability of the individual patient's tumor tissue needs to be assessed to find out whether single patients do not respond to HSV-1 therapy because of limited (i) infectivity, (ii) replication or (iii) vector distribution of vector particles within the tumors.
In addition to replication-conditional HSV-1 mutants, the 'gutless' HSV-1 amplicon vector has several properties, which make it a promising candidate gene transfer vehicle for clinical use. No virus proteins are encoded, it is nearly nontoxic when packaged without contaminating helper virus, it can infect most mammalian cell types and can accommodate large fragments of foreign DNA. 8, 18 For human application, the disadvantages of HSV-1 amplicons include their still somewhat limited titers (o1 Â 10 9 t.u. after concentration). Using HSV-1 amplicon vectors for gene therapy, the effectiveness primarily depends on the infectivity of the amplicon vector, as it is replication deficient. Packaging of amplicons into HSV-1 particles can be achieved either by the use of helper viruses 29, 30 or helper virus-free.
14 Although the development of improved helper virusdependent packaging systems has continuously increased the safety of the amplicon system, many problems associated with the helper virus still remained. 31 These include acute cytopathic effects induced by the helper virus, reversion of the helper virus to wt-HSV-1 phenotype by recombination and unreliability of transgene expression. Therefore, helper virus-free packaging systems were developed using replicationcompetent, packaging-defective genomes of HSV-1 to provide the functions necessary for replication and packaging of cotransfected amplicon DNA.
14,32-34 The resulting stocks of helper virus-free HSV-1 amplicons have been shown to be safe and efficient in culture and in vivo, and they transduce a variety of central nervous system-derived cells including human gliomas. 8, [13] [14] [15] [16] [35] [36] [37] Owing to the aforementioned characteristics, HSV-1 amplicons have great potential for clinical applications; however, studies of their infectivity in primary human glioma cell cultures have not been performed so far.
With regard to infectivity of human glioma cells by HSV-1-based vectors, various long-term human glioma cell cultures were used in various experimental HSV-1-based gene therapy protocols over the past 10 years, most of them relying on the use of replication-conditional vectors for virus-mediated oncolysis. Human U-87 glioblastoma cells have been successfully infected with hrR3, 38 ) and showed that the glioma cells varied 9.7-fold in their susceptibility to HSVmediated cytotoxicity. Replication-defective HSV-1 vectors have been successfully used in human U-87 glioblastoma cells in culture. 46, 47 However, due to limited distribution of vector particles in vivo, the therapeutic effect in the intracranial U87 model was negative. 47 Little data exist about helper virus-free HSV-1 amplicon vectors in human glioma cell lines so far. Lam et al 48 used an HSV/AAV hybrid amplicon vector to infect five different human glioma cell lines (Gli36, U87MG, U87MGDEGFR, T98G and U373), showing that 11-80% of all cells could be infected at an MOI of 0.5, depending on the cell line. Our own group demonstrated effective transduction of human U87DEGFR and Gli36DEGFR glioma cells in vivo by the replication-conditional HSV-1 mutants hrR3 and MGH-1 as well as by a universal helper virus-free HSV-1 amplicon vector, all vectors carrying marker genes for molecular imaging-guided gene therapy. 15, 49 In all the aforementioned examples, the HSV-1 vectors used for gene therapy were only tested on established, standardized cell culture models. This method neglects the variability of different human tumors, especially gliomas, in vivo. This variability is partly due to different histological types of tumors, but partly also due to interindividual differences between tumors of the same histological classification from different patients. On the molecular level, HSV-1 vector entry into cells is mediated by the binding of the viral surface glycoprotein D to cell surface receptors (eg HveC/HveA 50, 51 ). Variability in receptor expression has been described for different cell populations. 51, 52 Therefore, a variable infectability of different tumors by HSV vectors is most likely dependent on different expression levels of HSV entry receptors. We showed that only tumor cells expressing HveC could be successfully transduced with HSV-GFP, but not all nectin-1/HveC-positive cells were transduced with HSV-GFP. This finding suggests the existence of at least one more factor influencing the infectability by HSV vectors. As interferons are produced in cells as a defense to HSV-1 infection, 53 interferon receptor status should influence the infectability of cells by HSV vectors. Gliomas are known to vary in their interferon receptor density, 54 so infectability by HSV vectors might also correlate to interferon receptor status. Nevertheless, engineering of viral vectors with modified surface proteins to create increased affinity to cell entry receptors is a promising approach for optimizing gene therapy. 55 Maleniak et al 17 studied responses to adenoviralmediated gene therapy on primary cell cultures derived from surgical biopsies that were partly resistant to chemotherapy. The different primary glioblastoma cell cultures (n ¼ 5) were observed to vary in their infectivity by the adenoviral vector up to 14-fold, measured by enzyme activity assay delivered by the exogenous gene coding for b-galactosidase. We also found an up to 13.9-fold difference in the transduction efficiency between our primary CNS-derived tumor cultures (n ¼ 20). Tumor cells grown in primary cell culture generally showed an approximately seven-fold lower transduction efficiency compared to human Gli36DEGFR glioma cells and 2.5-fold lower transduction efficiency compared to BHK cells. These results suggest that primary tumor cells in vivo can be infected nearly as well as standardized cell lines in culture. However, interindividual differences in infectability have to be taken into account when translating experimental gene therapy protocols into clinical application. MacKie et al 56 examined the ability of wild-type HSV-1 and HSV-1716 to replicate in primary tumor cell lines, which was the case in 8/9 samples. Detta et al 57 determined the in vitro permissivity of glioblastomas and metastatic brain tumors for HSV-1716 replication. They found that the replication of this vector, which depends on the proliferation activity of the infected cells, is more efficient in metastatic brain tumors than in glioblastomas due to larger and more contiguous proliferative zones. Interestingly, with our replicationdeficient HSV amplicon vector, the higher-grade tumors (glioblastomas, metastases) were less susceptible to HSV-1 amplicon vector infection than the lower-grade tumors (anaplastic gliomas, meningioma). This suggests that HSV-1-based virus-and gene therapy might be more effective if initiated at an early disease stage in the stepwise progression of a lower-grade glioma to a glioblastoma, although this note should be taken cautiously because of the small sample number of lowgrade tumors. Moreover, data from those tumors that did not grow in cell culture could not be obtained. This may have ruled out tumors that may have been readily transduced by the virus.
We conclude that different types of brain neoplasms cultured as primary tumor cell culture can be efficiently infected with the helper virus-free HSV-1 amplicon vectors. Thus, gene therapy protocols employing HSV-1 amplicons should be feasible in the clinical application, especially in patients with gliomas. As the variability of infectivity of tumors from different patients has to be taken into account in designing clinical gene therapy, individual testing of tumor samples for infectivity by herpes virions might be of considerable value in the assessment of the induced therapeutic effect. Theoretically, testing before vector application would be sensible to perform, but it is difficult to envisage that an additional intervention procedure before virus administration would be supported either ethically or by the patient. No additional procedure, however, is necessary when primary tissue is being obtained directly before vector application. From the perspective to learn more about the efficiency of vectors in clinical application, knowledge on the variability of infectivity could be of considerable value in the long-term establishment of gene and virus therapy for patients with glioblastomas.
Materials and methods

Cell culture
Primary tumor cultures were derived from surgical biopsies of 42 patients. The study protocol was approved by the local Ethics Committee of the University of Cologne. Informed consent about culturing tumor tissue was obtained prior to surgery. Each tumor specimen was cut into small pieces, removing blood vessels, then resuspended in trypsin solution (4% in 0.01 M PBS, pH 7.2) and pipetted up and down several times. After incubation (371C, 10 min), Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Karlsruhe, Primary cell cultures of human brain tumors MA Rueger et al Germany) supplemented with 20% fetal bovine serum (FBS; Roche Diagnostics, Mannheim, Germany), 100 U/ml penicillin, 100 mg/ml streptomycin (P/S; Life Technologies) and 1% amphotericin (SIGMA, Steinheim, Germany) was added and the cell suspension was centrifuged (210 r.c.f., 6 min). The pellet was resuspended in DMEM with 20% FBS, 1% P/S and 1% amphotericin at 371C in a 5% CO 2 /95% air atmosphere. Human Gli36DEGFR glioma cells (kind gift of Dr David Louis, Molecular Neurooncology Laboratory, MGH, Boston, MA, USA; Ichikawa et al 58 ) and BHK-21 (ATCC, Rockville, MD, USA) were grown in DMEM containing 10% FBS and 1% P/S at 371C and 5% CO 2 /95% air atmosphere.
HSV-1 amplicon vector
The HSV-1 amplicon plasmid pHSV-GN containing the gene for green fluorescent protein (gfp) was a kind gift from Professor Xandra Breakefield (Neurogenetics Unit, MGH, Boston, MA, USA; Fraefel et al 59 ) and was packaged helper virus free as described previously 15 to generate HSV-GFP amplicon vector. Purified vector stocks were titrated (transducing units per ml; t.u./ml) on Gli36DEGFR and BHK cells by infecting confluent monolayers in 24-well plates (Falcon, Becton Dickinson, Heidelberg, Germany) and counting GFP-positive cells 24 h after infection. 15 Concentrated virus stocks (1 Â 10 8 t.u./ml) were stored at À801C for further use.
Infection and quantification
When primary tumor cell cultures formed nearly confluent monolayers, six-well plates were infected with 100 ml of HSV-GFP (1 Â 10 8 t.u./ml) in 2 ml DMEM supplemented with 2% FBS. For direct comparison, infection was also performed on Gli36DEGFR and BHK cells, which had been seeded on six-well plates in triplicate 1 day prior to infection in a concentration of 5 Â 10 5 cells per well. Incubation with HSV-GFP took place overnight at 371C. Next day, medium was changed to DMEM with 20% FBS, 1% P/S and 1% amphotericin. At 24 h after infection, the number of gfp-expressing cells was counted. Culture plates were examined by using a standard fluorescence microscope (Zeiss Axiovert 135, Carl Zeiss, Heidenheim, Germany). gfp-positive cells were counted in four representative fields of view, each covering 1/925 of the entire well. The total number of infected cells per well was determined by multiplying the mean of gfp-positive cells by 925. Transduction efficiency in primary cell cultures was calculated by dividing the respective number of infected cells per well by the mean number of infected Gli36DEGFR cells and BHK cells per well, respectively, resulting in the transduction efficiency in the primary tumor culture in percent. Representative images were acquired using a digital camera (INTAS, Göttingen, Germany) at standard camera settings for gain (6 dB) and exposure time (0.5 s). Cells were kept in DMEM supplemented with 20% FBS, 1% P/S and 1% amphotericin, and were observed twice a week for GFP expression until the expression ceased.
Immunohistochemistry
Confluent primary tumor cells were trypsinized, centrifuged (300 r.c.f., 5 min) and a concentrated cell suspension was plated onto coverslips and incubated (371C, 2 h). Coverslips were incubated over night in DMEM with 20% FBS, 1% P/S and 1% amphotericin. Next day, coverslips were washed (0.01 M PBS, pH 7.2), acetone was applied for 5 min, and then coverslips were allowed to dry. Anti-glial fibrillary acidic protein antibody (rabbit polyclonal anti-GFAP; DAKO) was applied in a concentration of 1:3000. For visualization of the primary antibody the biotin-streptavidin system kit (DCS) was used with 3,3 0 -diaminobenzidine (DAB) as dyeing agent. Phase-contrast microscopy at standard camera settings for gain (6 dB) and exposure time (0.008 s) was used for acquisition of representative images.
Ki67 staining was performed on primary tumor samples following standard protocols.
Herpes entry receptor status
Confluent primary tumor cells in six-well plates were infected with HSV-GFP as described above. At 24 h after infection, staining for herpes entry receptors was performed on those same cells. Rabbit polyclonal serum anti-human nectin-1 R165, a kind gift from Dr Gary Cohen (School of Dental Medicine) and Dr Roselyn J Eisenberg (School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA), was applied in a concentration of 1:100 in incubation buffer for 90 min. Anti-rabbit-cy3 (1:100 in incubation buffer) was applied as secondary antibody for 60 min.
Statistics
Descriptive statistics and regression analysis were performed with Microsoft Excel 2002 (Microsoft Corp.). Student's t-test was performed with SigmaStat 3.0 (SPSS Inc.); statistical significance was set at the less than 5% level (Po0.05).
